

National Immunization Survey-Child

Error Profile for the 2022 NIS-Child

Centers for Disease Control and Prevention

**National Center for Immunization
and Respiratory Diseases**

Presented by:

NORC at the University of Chicago

November 2023

Acknowledgments

The development and production of the Error Profile for the 2022 NIS-Child is a team effort that has included contributions from many individuals (listed in alphabetical order) in two organizations:

National Center for Immunization and Respiratory Diseases, CDC – Laurie D. Elam-Evans, Holly A. Hill, Sean Hu, and James A. Singleton.

NORC at the University of Chicago – Zachary H. Seeskin, Benjamin Skalland, Kirk Wolter, and Yuhei Koshino

Table of Contents

1. Introduction	1
2. Part I: Comparisons of NIS-Child Data to External Sources	2
2.1 Demographic Distributions: Comparison of NIS-Child Distributions to Population Distributions...	2
2.2 Comparison of NIS-Child and IISAR Vaccination Coverage	5
What is IISAR?	5
Visual Comparison of the Vaccination Coverage Estimates	6
Child Participation Rate (CPR)	7
Negative Relationship Between Difference in Vaccination Coverage and CPR	8
2.3 Comparison of Children by Type of Health Insurance Coverage	9
2.4 Comparison of Vaccination Coverage Estimates: NIS-Child v. State Immunization Surveys	11
3. Part II: Assessment of Total Survey Error for NIS-Child Vaccination Coverage Estimates	22
3.1 Sampling-Frame Coverage Error	24
3.2 Nonresponse Error	28
Components of Nonresponse in NIS-Child	28
Weight Adjustment for Nonresponse Error	29
Assessment of Nonresponse Error	29
NIS-Child Item Nonresponse Rates	32
3.3 Measurement Error	32
3.4 Sampling Error	34
3.5 Total Survey Error Distribution	35
3.6 Assessment of the Change in Bias Using the Bridging Cohort Method	38
4. Summary	39
References	43

List of Figures

Figure 2.1:	Scatterplot of NIS-Child (in %) v. IISAR (in %) Vaccination Coverage Estimates for the Combined 7-Vaccine Series: 56 Estimation Areas, 2021	6
Figure 2.2:	Scatterplot of NIS-Child (in %) v. IISAR (in %) Vaccination Coverage Estimates for the Combined 7-Vaccine Series: Six 2013-2017 Sentinel Sites, 2021	7
Figure 2.3:	Scatterplot of IISAR (in %) Vaccination Coverage Estimate for the Combined 7-Vaccine Series v. CPR (in %): 56 Estimation Areas, 2021	8
Figure 2.4:	Scatterplot of the Difference (NIS-Child Minus IISAR) for the Combined 7-Vaccine Series (in %) v. CPR (in %) with Regression Line: 56 Estimation Areas, 2021	9
Figure 2.5.1:	Comparison of Vaccination Coverage Estimates for Children 19-35 Months: Kansas Retrospective Vaccination Coverage Survey, 2014-2015 v. NIS-Child, 2015....	14
Figure 2.5.2:	Comparison of Vaccination Coverage Estimates for Children at 24 Months: Tennessee Immunization Status Survey, 2022 v. NIS-Child, 2022.....	15
Figure 2.5.3:	Comparison of Vaccination Coverage Estimates for Children at 24 Months: Virginia Annual Immunization Survey, 2021 v. NIS-Child, 2021	16
Figure 2.5.4:	Comparison of Vaccination Coverage Estimates for Children at 24 Months: Florida Immunization Survey, 2020 v. NIS-Child, 2020.....	17
Figure 2.5.5:	Comparison of Vaccination Coverage Estimates for Children 19-35 Months: Georgia Immunization Study, 2022 v. NIS-Child, 2022	18
Figure 2.5.6:	Comparison of Vaccination Coverage Estimates for Children 19-35 Months: Michigan Care Improvement Registry, 2022 v. NIS-Child, 2022	19
Figure 2.5.7:	Comparison of Vaccination Coverage Estimates for Children 19-35 Months: Washington Immunization Information System, 2022 v. NIS-Child, 2022.....	20
Figure 2.5.8:	Comparison of Vaccination Coverage Estimates for Children at 24 Months: Wisconsin Immunization Registry, 2022 v. NIS-Child, 2022	21

List of Tables

Table 2.1:	One-Way Demographic Distributions Among Children with Adequate Provider Data vs. Population Distributions: NIS-Child, 2022	4
Table 2.2:	Comparison of Alternative Estimates of Health Insurance Coverage Among Child: NIS-Child, ACS, CPS ASEC, and NHIS for 2021 and NIS-Child, CPS ASEC, and NHIS for 2022	10
Table 2.3:	Sample Sizes of Children from State Immunization Surveys in 2015, 2020, 2021, and 2022	13
Table 3.1:	Percentage of Age-Eligible Children in the Population by Telephone Status by Year: NIS-Child, United States, 2012-2021	25
Table 3.2:	Vaccination Coverage Estimates and Standard Errors of Select Vaccines and Vaccine Series for the Cell-Phone and LLO Domains: NIS-Child, United States, 2017	26
Table 3.3:	Vaccination Coverage Estimates and Standard Errors of Select Vaccines and Vaccine Series for Children 19-35 Months in the Cell-Phone and Phoneless Domains: NHIS-PRC, United States, 2012	27
Table 3.4:	Preliminary Assessment of Sampling-Frame Coverage Error and Mean True Vaccination Coverage (in %): NIS-Child, United States, 2022	28
Table 3.5:	Estimates of Nonresponse Error for Vaccination Coverage (%) Derived from Estimates Based on NHIS Imputations and NIS-Child Estimates	31
Table 3.6:	Item Nonresponse Rates, NIS-Child Household Interview, United States, 2022	32
Table 3.7:	Estimated Under-Reporting Error by Vaccine Series: NIS-Child, United States, 2017 and 2019	34
Table 3.8:	Vaccination Coverage Estimates and Standard Errors Using Design Weights and Final Weights: NIS-Child, United States, 2022	35
Table 3.9:	Total Survey Error Model Inputs by Stages: NIS-Child, United States, 2022	36
Table 3.10:	Mean and 95% Credible Interval for the Estimated TSE Distribution and Component Error Distributions: National Immunization Survey-Child, United States, 2022	36
Table 3.11:	Difference between the Estimates* for the Bridging Birth Cohort† by Age 19 Months: NIS-Child, United States, 2021 vs. 2022	39

1. Introduction

Total survey error (TSE) is the difference between a survey estimate and the true value of the corresponding population parameter. TSE is the net effect of sampling error and all forms of nonsampling error, including sample-frame coverage error, error due to survey nonresponse, and errors of measurement (such as reporting, record checking, coding, and other processing errors). TSE excludes conceptual errors committed in deciding what should be measured in the survey and judgmental errors made in interpreting the survey findings or in making public policy based on the survey data.

The main aim of this report is to provide a well-rounded but brief discussion of what is known about TSE for the 2022 NIS-Child. A recent report describes TSE for the 2022 NIS-Teen (CDC, 2023b). The statistics and methodology of the NIS have been described by Smith et al. (2005) and Wolter et al. (2017).

The report is written in two parts. The first part, which appears in Section 2, compares NIS-Child statistics to corresponding benchmarks derived from censuses or large reference surveys, such as the National Health Interview Survey and the American Community Survey. A large difference between an NIS-Child statistic and its corresponding benchmark is likely a signal of error in the NIS-Child or of definitional differences between the NIS-Child and benchmark concepts. A small difference may be a signal of good accuracy in the NIS-Child or simply an indicator that the NIS-Child statistic and its benchmark are consistent with one another. This part of the report examines demographic statistics, vaccination coverage, and health insurance statistics.

The second part of the report, set forth in Section 3, focuses attention on the NIS-Child estimated vaccination coverage. The material presents what is known from special evaluation studies about the component errors and the total error in vaccination coverage estimates. The section culminates with discussion of the distribution of TSE in the 2022 NIS-Child and of the change in TSE between the 2021 and 2022 NIS-Child.

Both parts of the report are conducted at the national level. The report closes in Section 4 with a summary of findings and limitations.

Throughout the report, we analyze the following vaccines and vaccine series:

- diphtheria, tetanus, and acellular pertussis vaccine (DTaP), ≥ 4 doses (4+ DTaP);
- poliovirus vaccine, ≥ 3 doses (3+ Polio);
- measles, mumps, and rubella vaccine (MMR), ≥ 1 dose (1+ MMR);

- the full series of *Haemophilus influenzae* type b conjugate vaccine (Hib), ≥ 3 doses or ≥ 4 doses depending on brand (Hib-FS);¹
- hepatitis B vaccine (HepB), ≥ 3 doses (3+ HepB);
- hepatitis B dose within 3 days of birth (HepB birth dose);
- varicella vaccine, ≥ 1 dose (1+ Var);
- pneumococcal conjugate vaccine (PCV), ≥ 4 doses (4+ PCV); and
- the combined 7-vaccine series (≥ 4 doses of DTaP, ≥ 3 doses of poliovirus vaccine, ≥ 1 dose of measles-containing vaccine, the full series of Hib, ≥ 3 doses of HepB, ≥ 1 dose of varicella vaccine, and ≥ 4 doses of PCV).

For the analysis of TSE, we focus on 4+ DTaP, 1+ MMR, HepB birth dose, and the combined 7-vaccine series.

2. Part I: Comparisons of NIS-Child Data to External Sources

We begin by comparing NIS-Child demographic distributions (child's age, child's sex, mother's race and ethnicity, mother's education, and mother's age) to benchmark distributions derived from National Vital Statistics System (NVSS) natality data and other sources. Second, we compare NIS-Child vaccination coverage estimates to estimates provided by the Immunization Information Systems Annual Report. Third, we compare health insurance distributions derived from the NIS-Child Health Insurance Module (HIM) to corresponding distributions obtained from (i) the American Community Survey (ACS), (ii) the National Health Interview Survey (NHIS), and (iii) the Current Population Survey Annual Social and Economic Supplement (CPS ASEC). Finally, we compare NIS-Child vaccination coverage estimates to corresponding coverage estimates produced by state immunization surveys.

2.1 Demographic Distributions: Comparison of NIS-Child Distributions to Population Distributions

A direct method of estimating survey error is to compare the survey estimates to benchmark estimates from other, higher quality sources. While high-quality benchmark estimates of national-level vaccination coverage are not available, we can compare the survey estimates of demographic distributions to those

¹ At times in this report, we also refer to the Hib primary series (Hib-PS) which is ≥ 2 doses or ≥ 3 doses depending on brand. We also refer to ≥ 3 doses of Hib vaccine as 3+ Hib.

derived from NVSS natality data. These data yield population counts for several important characteristics of children: mother's race and ethnicity, mother's education, mother's age, child's sex, and child's age.

To create benchmark population demographic distributions for children aged 19 to 35 months in 2022, we began by obtaining the counts of live births from the 2019 and 2020 NVSS natality data for children that would be 19 to 35 months old as of July 1, 2022, the midpoint of the reference year. These counts were obtained overall and by mother's race and ethnicity, mother's education, mother's age, child's sex, and child's age as of July 1, 2022. The raw NVSS counts were then adjusted to account for infant mortality and immigration into the United States to produce counts of children aged 19 to 35 months living in the United States on July 1, 2022. These adjustments were applied separately by race and ethnicity group to account for differences in mortality and immigration across these groups.

We produced 2022 NIS-Child national-level demographic distribution estimates first using design weights and then using final weights. The design weights reflect the sample design but do not include any adjustments for sampling-frame noncoverage or interview nonresponse and are not calibrated to population control totals. Final weights are the design weights, with adjustments for noncoverage, nonresponse, and calibration to population control totals. (See the footnotes to Table 2.1 for the demographic variables used in this calibration.)

Table 2.1 compares 2022 NIS-Child national-level survey estimates of demographic distributions for children with adequate provider data to benchmark distributions for child's age, sex, mother's race and ethnicity, mother's education, and mother's age. We observe that the survey distribution for child's age and child's sex is close to the population distribution, even when using the design weights. The differences are zero when the final weights are used due to calibration based on child's age and child's sex. The design-weighted distribution of mother's race and ethnicity differs somewhat from the population distribution, with the largest differences being for non-Hispanic White only mothers (59.4 percent in survey, 51.0 percent in population), Hispanic mothers (18.7 percent in survey, 24.4 percent in population), and non-Hispanic Black only children (11.3 percent in survey, 14.7 percent in population). The differences are small when the final weights are used due to calibration using race and ethnicity.

Differences between the respondent set and the population are also observed for mother's education and mother's age. For mother's education, the respondent set over-represents children whose mothers have a four-year college degree when the design weights are used (53.0 percent in survey, 33.7 percent in population) and under-represents children whose mothers do not have a four-year college degree. When the final weights are used, the survey still somewhat over-represents children whose mothers have a four-year college degree (40.2 percent in survey, 33.7 percent in population) and under-represents children whose mothers have some college but not a four-year degree (21.2 percent in survey, 27.8 percent in population). The survey also over-represents children whose mothers are age 30 or older when the final weights are used (67.2 percent in survey, 62.5 percent in population) and under-represents children whose mothers are age 20 to 29 (31.8 percent in survey, 36.5 percent in population).

Table 2.1: One-Way Demographic Distributions Among Children with Adequate Provider Data vs. Population Distributions: NIS-Child, 2022

Demographic Domain	Population Distribution (%)	Design-Weighted Estimates		Final-Weighted Estimates*	
		Survey Distribution (%)	Survey – Population	Survey Distribution (%)	Survey – Population
Child’s Age					
19-23 months	29.3	29.3 ± 1.3	0.0 ± 1.3	29.3 ± 1.3	0.0 ± 1.3
24-29 months	33.9	32.0 ± 1.7	-1.9 ± 1.7	33.9 ± 1.4	0.0 ± 1.4
30-35 months	36.8	38.7 ± 1.6	1.9 ± 1.6	36.8 ± 1.4	0.0 ± 1.4
Child’s Sex					
Male	51.1	52.1 ± 1.7	0.9 ± 1.7	51.1 ± 1.4	0.0 ± 1.4
Female	48.9	47.9 ± 1.7	-0.9 ± 1.7	48.9 ± 1.4	0.0 ± 1.4
Mother’s Race and Ethnicity					
Hispanic	24.4	18.7 ± 1.7	-5.6 ± 1.7	24.1 ± 1.5	-0.3 ± 1.5
White	51.0	59.4 ± 1.7	8.4 ± 1.7	50.8 ± 1.5	-0.2 ± 1.5
Black	14.7	11.3 ± 1.1	-3.5 ± 1.1	15.0 ± 1.1	0.3 ± 1.1
Other	9.9	10.6 ± 0.9	0.7 ± 0.9	10.0 ± 0.9	0.1 ± 0.9
Mother’s Education					
Less than high school	12.1	6.4 ± 0.9	-5.7 ± 0.9	10.6 ± 1.1	-1.5 ± 1.1
High school	26.5	15.4 ± 1.1	-11.0 ± 1.1	27.9 ± 1.5	1.5 ± 1.5
Some college	27.8	25.2 ± 1.6	-2.6 ± 1.6	21.2 ± 1.2	-6.6 ± 1.2
4-year college graduate	33.7	53.0 ± 1.7	19.3 ± 1.7	40.2 ± 1.4	6.6 ± 1.4
Mother’s Age					
< 20 years	1.0	0.5 ± 0.2	-0.5 ± 0.2	0.9 ± 0.4	0.0 ± 0.4
20-29 years	36.5	26.2 ± 1.6	-10.3 ± 1.6	31.8 ± 1.5	-4.7 ± 1.5
>= 30 years	62.5	73.3 ± 1.6	10.8 ± 1.6	67.2 ± 1.5	4.8 ± 1.5

NOTE: Excludes U.S. territory samples. Table presents survey estimate and 95% confidence interval and presents the difference between the survey and the population percentages, along with a 95% confidence interval for the difference, assuming no error in the population proportion.

* Final provider-phase weights are calibrated within each geographic estimation area to marginal totals for child's age (19-23, 24-29, 30-35), child's sex (male, female), child's race and ethnicity (Hispanic, Black, other), mother's education (high school or less, more than high school), household telephone status (cell-phone only, other), and quintile of the estimated propensity to have adequate provider data for the child, given the household interview was completed for the child. The marginal totals for child's race and ethnicity are estimated by summing the final household-phase weight within each category; the final household-phase weight itself had been calibrated to marginal control totals for mother's race and ethnicity.

Comparisons of demographic distributions were made between survey estimates and population values for all two-way combinations of child's age, child's sex, mother's race and ethnicity, and mother's education, first using design weights and then using final weights. While final weights are controlled to marginal population totals for these characteristics individually, the weights are not controlled to totals

for cross-classifications of these characteristics. Differences between survey estimates and population values for these cross-classifications are all less than 5.0 percentage points when final weights are used.

2.2 Comparison of NIS-Child and IISAR Vaccination Coverage

This subsection compares NIS-Child vaccination coverage Immunization Information System Annual Report (IISAR) data in 2021.² The comparison is given for the combined 7-vaccine series using the data available from IISAR, recognizing that the findings may not apply to other vaccine series. Agreement between the vaccination coverage estimates signals consistency between NIS-Child and IISAR, and it may signal that both sources provide an accurate measurement of the true vaccination coverage in the age-eligible child population (19- to 35-month-old children). Lack of agreement between the vaccination coverage estimates signals inconsistency and that one or both sources are less accurate.

Our work in this subsection is divided into four parts. First, we describe the IISAR and some definitions we will use in this analysis. Second, we compare visually the vaccination coverage estimates in NIS-Child and IISAR using scatterplots. Third, we introduce the concept of the IIS (Immunization Information System)³ Child Participation Rate (CPR). Finally, we demonstrate through regression analysis that the difference between the combined 7-vaccine series vaccination coverage estimates in NIS-Child and IISAR is related to the CPR.

What is IISAR?

The IISAR is an annual assessment of IIS activity among the 64 immunization program awardees, which include the 50 states, 6 cities (Chicago, District of Columbia, Houston, New York City, Philadelphia, and San Antonio), and 8 U.S. territories (American Samoa, Guam, Marshall Islands, Micronesia, Northern Mariana Islands, Palau, Puerto Rico, and Virgin Islands). To evaluate each awardee's performance, the immunization program manager in the awardee area is asked to complete a self-administered, web-based questionnaire asking for demographic and immunization information, public and private provider site participation levels, and information about fulfillment of IIS functional standards. Because the questionnaire is self-administered and web-based, some awardees may report partial data or no data at all.

NCIRD provided competitive supplemental funds to grantees that have achieved consistently high standards. During the period 2013-2017, six grantees have been recognized as *sentinel sites*, including

² <https://www.cdc.gov/vaccines/programs/iis/annual-report-iisar/overview.html>

³ State IIS are computer databases that aspire to contain information about all of the doses of all vaccines administered to all children residing within the state. It is known that different state IIS vary in their completeness of both children and the doses they received. <https://www.cdc.gov/vaccines/programs/iis/about.html>


Michigan, Minnesota, North Dakota, New York City, Oregon, and Wisconsin.⁴ Because of the higher standards they achieved regarding participation rates and other indicators of IIS quality, vaccination coverage estimates reported in IISAR by sentinel sites are thought to be relatively more accurate than vaccination coverage estimates reported by non-sentinel sites. In this analysis, the sentinel sites are referred to as *2013-2017 sentinel sites*.

In what follows, we compare 2021 NIS-Child vaccination coverage estimates to 2021 IISAR coverage estimates. Because 2022 IISAR vaccination coverage estimates are not available as of this writing, the 2021 comparison will serve as the most current information available about the relative accuracy of the 2022 NIS-Child.

Visual Comparison of the Vaccination Coverage Estimates


Figures 2.1 and 2.2 display plots of the NIS-Child vaccination coverage estimate versus the IISAR vaccination coverage estimate for the combined 7-vaccine series in year 2021. Figure 2.1 includes 56 of the estimation areas used in the NIS-Child; it does not include points corresponding to 8 U.S. territories. Figure 2.2 includes only the six 2013-2017 sentinel sites.

Figure 2.1: Scatterplot of NIS-Child (in %) v. IISAR (in %) Vaccination Coverage Estimates for the Combined 7-Vaccine Series: 56 Estimation Areas, 2021



⁴ <https://www.cdc.gov/vaccines/programs/iis/activities/sentinel-sites.html>

Figure 2.2: Scatterplot of NIS-Child (in %) v. IISAR (in %) Vaccination Coverage Estimates for the Combined 7-Vaccine Series: Six 2013-2017 Sentinel Sites, 2021



In all plots, the straight line through the origin reflects the $y = x$ line. Points above the line represent areas in which the NIS-Child vaccination coverage estimate is greater than the IISAR estimate, and points below the line represent areas in which the IISAR estimate is greater. The line itself represents complete agreement between the NIS-Child and IISAR estimates. In addition, the color and symbol for the point signify the magnitude of the difference between the NIS-Child and IISAR estimates.

The plots reveal that in most areas the NIS-Child vaccination coverage estimates are greater than the IISAR estimates. There is reasonably good agreement between the two estimates for the six 2013-2017 sentinel sites. Generally, IISAR estimates tend to be lower in non-sentinel areas. For IIS that achieve high standards, NIS-Child and IISAR vaccination estimates are reasonably similar.


Child Participation Rate (CPR)

To test the hypothesis that increasing quality of a state's IIS data implies increasing agreement between the NIS-Child and IISAR vaccination coverage estimates, we introduce the CPR and evaluate it as a possible measure of the quality of the IIS. The CPR is defined as the proportion of children in the area who have two or more doses of any vaccine recorded in the IIS relative to a U.S. Census Bureau count of children living in the area. Note that the use of two data sources can result in some IISAR CPR values being greater than 100 percent. In Figure 2.3, we plot the IISAR vaccination coverage estimate for the combined 7-vaccine series versus the CPR for the year 2021, including 56 core estimation areas. Points for the six 2013-2017 sentinel sites are labeled, and these sites are generally located in

the upper right corner of the plot, corresponding to higher values of both the CPR and vaccination coverage estimates.

We fit a linear regression model to the points in Figure 2.3 and the corresponding fit is represented by the solid line depicted in the figure. The association of CPR with the IISAR vaccination coverage estimate is positive and statistically significant. The Pearson correlation is 0.527 with a 95% confidence interval of [0.306, 0.694]. Therefore, we conclude that CPR is positively associated with the completeness of the vaccination histories of the children. CPR appears to be a reasonable, but not necessarily comprehensive, measure of the quality of data in the IIS databases.

Figure 2.3: Scatterplot of IISAR (in %) Vaccination Coverage Estimate for the Combined 7-Vaccine Series v. CPR (in %): 56 Estimation Areas, 2021




Negative Relationship Between Difference in Vaccination Coverage and CPR

We conduct further evaluation of the hypothesis that increasing quality of state IIS data is associated with increasing agreement between the NIS-Child and IISAR vaccination coverage estimates. Specifically, taking CPR to be the measure of IIS quality, we calculated the difference between the combined 7-vaccine series coverage estimates in NIS-Child and IISAR and fit a simple linear regression model relating the difference to the CPR. Figure 2.4 presents the scatterplot of the difference versus the CPR for the set of 56 core estimation areas in 2021, and the straight line depicted in the figure is the regression line. The CPR has a statistically significant relationship with the difference for all years. The coefficient on the CPR is negative (-0.64 percentage points with a 95% confidence interval of [-0.95, -0.33]), which implies that the difference declines with increasing CPR, or in other

words, the difference between NIS-Child and IISAR vaccination coverage estimates declines as IIS quality increases. As the CPR, as an indicator of IIS data quality, increases, IISAR vaccination estimates tend to converge towards NIS-Child vaccination estimates, thus potentially supporting the accuracy of the NIS-Child vaccination coverage estimates.

Figure 2.4: Scatterplot of the Difference (NIS-Child Minus IISAR) for the Combined 7-Vaccine Series (in %) v. CPR (in %) with Regression Line: 56 Estimation Areas, 2021



We conducted an additional analysis pooling the data over the period 2016 to 2021 to achieve greater precision and regressed the difference between NIS-Child and IISAR vaccination coverage estimates on CPR, dummy variables for year, and state dummy variables. Similar to the results for 2021 in Figure 2.4, the pooled results showed that CPR has a statistically significant, negative relationship with the difference, with a regression slope coefficient of -0.15 percentage points with a 95% confidence interval of [-0.27, -0.03].

Summarizing, we have presented evidence in this section that the CPR is a reasonable, though not comprehensive, measure of the quality of IIS data for children. As state IIS data quality indicators improve, the difference between the NIS-Child and IISAR vaccination coverage estimates declines.

2.3 Comparison of Children by Type of Health Insurance Coverage

In this subsection, we compare NIS-Child health insurance estimates to those from the ACS, CPS ASEC, and the NHIS. We discuss the percentages of children with any private insurance coverage, any

public insurance coverage, and no insurance coverage. Before reviewing the results of the table, we provide an overview of each data source.

Conducted by the U.S. Census Bureau, the ACS is an ongoing survey that provides essential information about the population of the United States on a yearly basis, including statistics related to social, housing, economic, and demographic characteristics of the population. Table 2.2 contains information on the health insurance status of the child population 12 to 35 months based on the 2021 ACS⁵ at the national level. ACS interviews are conducted throughout the calendar year, and the ACS instrument assesses health insurance status as of the date of the interview.

Table 2.2: Comparison of Alternative Estimates of Health Insurance Coverage Among Child: NIS-Child, ACS, CPS ASEC, and NHIS for 2021 and NIS-Child, CPS ASEC, and NHIS for 2022

Type of Health Insurance Coverage	2021				2022		
	ACS	CPS ASEC	NHIS	NIS-Child ^a	CPS ASEC	NHIS	NIS-Child ^a
Any private ^b	54.5%	58.5%	52.4%	52.3%	58.1%	47.3%	53.7%
Any public ^c	47.1%	42.1%	46.2%	57.5%	42.7%	51.0%	56.1%
Uninsured ^d	4.2%	5.0%	2.8%	1.9%	4.7%	4.3%	1.9%

^aNIS-Child estimates were produced among children with adequate provider data using the final NIS-Child weight, which has been adjusted for noncoverage and nonresponse and calibrated to demographic population control totals.

^bPrivate: Includes coverage provided through an employer or union or purchased directly from an insurance company that helps pay for both doctor visits and hospital stays.

^cPublic: Includes Medicaid, CHIP, Indian Health Service, TRICARE, CHAMPUS and CHAMP-VA.

^dUninsured: Defined as an uninsured if they do not have private insurance that helps pay for both doctor visits and hospital stays and do not have any other form of health insurance.

CPS ASEC is conducted in March of every year. While CPS is a monthly household survey conducted by the U.S. Census Bureau and the Bureau of Labor Statistics and designed mainly for measuring employment and unemployment, CPS ASEC provides additional detailed statistics related to household income, poverty, health insurance status, and other topics. The CPS ASEC asks current health insurance coverage status as of the time of the interview. Based on data from the March 2021 and 2022 CPS ASEC⁶, national-level estimates of the health insurance distribution in 2021 and 2022 among children aged 12 to 35 months are shown in Table 2.2.

The NHIS is a cross-sectional household interview survey, conducted by the National Center for Health Statistics, that covers the civilian noninstitutionalized population in the United States. The objective of the NHIS is to monitor the health status of the U.S. population. In addition to collecting variables related

⁵ U.S. Census Bureau. 2021 ACS PUMS Data. Retrieved from <https://www.census.gov/programs-surveys/acs/microdata/access/2021.html>

⁶ U.S. Census Bureau. 2021 and 2022 ASEC dataset. Retrieved from <https://www.census.gov/data/datasets/time-series/demo/cps/cps-asec.html>

to health status, the survey collects many demographic and socioeconomic characteristics of household members. NHIS⁷ national-level estimates of the health insurance distribution in 2021 and 2022 for children aged 12 to 35 months are shown in Table 2.2. In the NHIS, health insurance status is assessed as of the time of the interview.

In reviewing Table 2.2, we find NIS-Child estimates, which are based on 19- to 35-month-old children as of the date of the interview, of the size of the privately-insured population to be lower than those from the ACS, CPS ASEC, comparable to the NHIS in 2021, and higher than the NHIS in 2022. We find the estimates for public health insurance in NIS-Child to be larger than the corresponding estimates from ACS, CPS ASEC, and NHIS. Finally, we find NIS-Child estimates of the size of the uninsured population tend to be less than corresponding estimates from ACS, CPS ASEC, and NHIS. The differences in estimates between the NIS-Child and the other three sources could be due to differential sample-frame coverage error, nonresponse error, or measurement error; to differences in the ages of the children targeted by the estimates; or to definitional differences (questionnaire differences) in how health insurance status is measured.

2.4 Comparison of Vaccination Coverage Estimates: NIS-Child v. State Immunization Surveys

In this subsection, we compare vaccination coverage estimates from NIS-Child and state immunization surveys. Agreement between the estimates signals consistency between the two sources and may indicate the accuracy of the sources. Disagreement between the estimates signals inconsistency and that at least one of the sources may be inaccurate. Eight state immunization surveys have been identified and included in the analysis, including surveys in Florida, Georgia, Kansas, Michigan, Tennessee, Virginia, Washington, and Wisconsin. As of this writing, we are unaware of immunization surveys sponsored or conducted by other states.

The Kansas Retrospective Vaccination Coverage Survey (KRS)⁸ and Virginia Annual Immunization Survey (VAIS)⁹ are based on random samples of students selected from public and private kindergartens and retrospective collection of students' vaccination statuses from school records. The Tennessee Immunization Status Survey (TIS)¹⁰ and Florida Immunization Survey (FIS)¹¹ are based on random samples of children selected from state listings of registered births. The Georgia Immunization

⁷ NHIS - Data, Questionnaires and Related Documentation. Retrieved from <https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm>

⁸ <https://www.kdhe.ks.gov/ArchiveCenter/ViewFile/Item/1642>

⁹ <https://www.vdh.virginia.gov/content/uploads/sites/11/2016/04/VAISAgRates.pdf>

¹⁰ <https://www.tn.gov/content/dam/tn/health/documents/cedep-weeklyreports/2022-24-Month-Old-Survey.pdf>

¹¹ <https://www.floridahealth.gov/programs-and-services/immunization/resources/surveys/documents/2yo2020.pdf>

Study (GIS)¹², Michigan Care Improvement Registry (MCIR)¹³, Washington Immunization Information System (WAIIS)¹⁴, and Wisconsin Immunization Registry (WIR)¹⁵ prepare estimates of vaccination coverage by sampling children from the state IIS and aggregating IIS vaccination histories for the selected children.

We compare estimates from the state surveys to corresponding estimates from the NIS-Child. The year of the comparison varies from state to state, and we always conduct the comparison for the most recent year data from the state survey are available. Table 2.3 gives the sample sizes of the state immunization surveys, where we find the available sample sizes of each state survey is much larger than the NIS-Child sample size in the state.

Figures 2.5.1 to 2.5.8 depict the vaccination coverage estimates for each of the eight states. The age range of the comparison also varies from state to state, depending on what range each state reports. For four of the states, the vaccination coverage estimates are compared at 24 months, and for these states the NIS-Child estimates are calculated in terms of vaccination status at 24 months for the set of children with adequate provider data who were 24 to 35 months at the time of the interview. For the remaining four states, the vaccination coverage estimates are compared for children 19 to 35 months.

The estimates for Hib vaccine and the combined 7-vaccine series are not always strictly comparable. For all eight state figures, we report the NIS-Child Hib vaccination coverage estimate and the combined 7-vaccine series vaccination coverage estimate in terms of Hib full series, which requires 3 or 4 doses of Hib, depending on the brand of Hib vaccine used. The Tennessee and Florida surveys also report in terms of Hib full series, yet the Kansas, Virginia, Georgia, Michigan, Washington, and Wisconsin surveys appear to report the Hib and the combined 7-series estimates in terms of 3+ Hib, although state documentation is not fully clear. NIS-Child vaccination coverage estimates for Hib may appear to be lower than some of the corresponding state Hib vaccination coverage estimates due to this noncomparability.

¹² https://immunizationstudyreports.s3.amazonaws.com/Child+Report/Child_Report_2022.html#summary

¹³ <https://www.michigan.gov/mdhhs/adult-child-serv/childrenfamilies/immunization/localhealthdepartment/county-immunization-report-card>

¹⁴ <https://doh.wa.gov/data-and-statistical-reports/washington-tracking-network-wtn/immunization-data/county-public-health-measures-dashboard>

¹⁵ <https://www.dhs.wisconsin.gov/publications/p02003a.pdf>

Table 2.3: Sample Sizes of Children from State Immunization Surveys in 2015, 2020, 2021, and 2022


Survey	2015	2020	2021	2022	
	Children 19-35 Months	Children 24-35 Months	Children 24-35 Months	Children 24-35 Months	Children 19-35 Months
Florida Immunization Survey (FIS)		5,518 ¹⁾			
NIS-Child in Florida, Children with Adequate Provider Data		335			
Georgia Immunization Survey (GIS)					337,803 ²⁾
NIS-Child in Georgia, Children with Adequate Provider Data					304
Kansas Retrospective Vaccination Coverage Survey (KRS)	7,881 ³⁾				
NIS-Child in Kansas, Children with Adequate Provider Data	228				
Michigan Care Improvement Registry (MCIR)					165,763 ⁴⁾
NIS-Child in Michigan, Children with Adequate Provider Data					457
Tennessee Immunization Status Survey (TIS)				1,399 ⁵⁾	
NIS-Child in Tennessee, Children with Adequate Provider Data				347	
Virginia Annual Immunization Survey (VAIS)			N/A ⁶⁾		
NIS-Child in Virginia, Children with Adequate Provider Data			520		
Washington Immunization Information System (WAIS)					129,860 ⁷⁾
NIS-Child in Washington, Children with Adequate Provider Data					394
Wisconsin Immunization Registry (WIR)				N/A ⁸⁾	
NIS-Child in Wisconsin, Children with Adequate Provider Data				278	

Source:

- 1) <https://www.floridahealth.gov/programs-and-services/immunization/resources/surveys/documents/2yo2020.pdf>
- 2) https://immunizationstudyreports.s3.amazonaws.com/Child+Report/Child_Report_2022.html#summary
- 3) <https://www.kdhe.ks.gov/ArchiveCenter/ViewFile/Item/1642>
- 4) <https://www.michigan.gov/mdhhs/adult-child-serv/childrenfamilies/immunization/localhealthdepartment/county-immunization-report-card>
- 5) <https://www.tn.gov/content/dam/tn/health/documents/cedep-weeklyreports/2022-24-Month-Old-Survey.pdf>
- 6) <https://www.vdh.virginia.gov/content/uploads/sites/11/2016/04/VAISAgRates.pdf>
- 7) <https://doh.wa.gov/data-and-statistical-reports/washington-tracking-network-wtn/immunization-data/county-public-health-measures-dashboard>
- 8) <https://www.dhs.wisconsin.gov/publications/p02003a.pdf>


The Kansas KRS and NIS-Child vaccination coverage estimates are compared in Figure 2.5.1. Because KRS vaccination coverage estimates are assessed at 35 months of age, one might expect them to be somewhat higher than NIS-Child estimates, which are based on children aged 19 to 35 months. Nevertheless, we find general agreement between the KRS and NIS-Child estimates. While the smallest absolute difference is 0.7 percentage points for 3+ Polio in Figure 2.5.1, the largest is 6.2 percentage points for 4+ PCV. Note that the KRS Hib and combined 7-vaccine series estimates may be based on a 3+ Hib definition rather than the Hib full series definition, limiting comparability between the two sources for these estimates.

Figure 2.5.1: Comparison of Vaccination Coverage Estimates for Children 19-35 Months: Kansas Retrospective Vaccination Coverage Survey, 2014-2015 v. NIS-Child, 2015




The Tennessee TIS and NIS-Child estimates are compared for children at age 24 months in Figure 2.5.2. We find a reasonable degree of agreement between the two sets of estimates. While the smallest absolute difference is 0.1 percentage points for 4+ PCV, the largest absolute difference is 9.3 percentage points for the combined 7-vaccine series.

Figure 2.5.2: Comparison of Vaccination Coverage Estimates for Children at 24 Months: Tennessee Immunization Status Survey, 2022 v. NIS-Child, 2022




The Virginia VAIS and NIS-Child estimates are compared for children at age 24 months in Figure 2.5.3. We find good agreement between the two sets of estimates, except for the Hib full series; the Hib full series vaccination coverage is estimated to be 9.1 percentage points higher in the VAIS than in the NIS-Child. However, note that the VAIS Hib estimate may be based on a 3+ Hib definition rather than the Hib full series definition, limiting comparability between the two sources.

Figure 2.5.3: Comparison of Vaccination Coverage Estimates for Children at 24 Months: Virginia Annual Immunization Survey, 2021 v. NIS-Child, 2021



Figures 2.5.4 presents the comparisons for children at 24 months for the Florida FIS. The FIS uses vaccination history data from the state IIS, and in the event the child is not up-to-date according to this history, makes an effort to contact the child's parent or guardian to obtain any vaccinations missing from the IIS history. Note that the FIS Hib estimate may be based on a 3+ Hib definition rather than the Hib full series definition, limiting comparability between the two sources.

Figure 2.5.4: Comparison of Vaccination Coverage Estimates for Children at 24 Months: Florida Immunization Survey, 2020 v. NIS-Child, 2020



Figures 2.5.5, 2.5.6, 2.5.7 and 2.5.8 present vaccination coverage estimates in Georgia, Michigan, Washington, and Wisconsin, respectively. In these states, the vaccine-to-vaccine pattern revealed in the states' estimates are generally similar to NIS-Child estimates. The differences between state and NIS-Child estimates are smaller in Georgia and Wisconsin than in Michigan and Washington. For all four states, NIS-Child estimates tend to be larger than the state estimates. Note that the Hib and combined 7-vaccine series estimates for these four state surveys may be based on a 3+ Hib definition rather than the Hib full series definition, limiting comparability to the NIS-Child for these estimates.

Figure 2.5.5: Comparison of Vaccination Coverage Estimates for Children 19-35 Months: Georgia Immunization Study, 2022 v. NIS-Child, 2022




Figure 2.5.6: Comparison of Vaccination Coverage Estimates for Children 19-35 Months: Michigan Care Improvement Registry, 2022 v. NIS-Child, 2022




Figure 2.5.7: Comparison of Vaccination Coverage Estimates for Children 19-35 Months: Washington Immunization Information System, 2022 v. NIS-Child, 2022





Figure 2.5.8: Comparison of Vaccination Coverage Estimates for Children at 24 Months: Wisconsin Immunization Registry, 2022 v. NIS-Child, 2022



In summary, there is a reasonable agreement in vaccination coverage estimates between NIS-Child and KRS, TIS, VAIS, and FIS. Because of follow-up interviews conducted with parents of children who are not up-to-date according to IIS vaccination histories, GIS vaccination estimates may be differentially biased upwards relative to NIS-Child estimates. On the other hand, NIS-Child vaccination coverage estimates are relatively higher than state estimates in Michigan, Washington, and Wisconsin, which rely on IIS vaccination histories as the source of their coverage estimates. Definitional differences used in accounting for Hib vaccine cloud the comparisons between state and NIS-Child estimates.

3. Part II: Assessment of Total Survey Error for NIS-Child Vaccination Coverage Estimates

In this second part of the report, we assess the total survey error in NIS-Child vaccination coverage estimates using the framework developed and implemented in Molinari et al. (2011) and Wolter et al. (2017). We decompose TSE into components of sampling and nonsampling error, and then assemble the best information available about the magnitude of each component error from specialized evaluation studies. We view each component error as a random variable subject to a conditional distribution, given the outcome of the NIS-Child. The mean of the conditional distribution is estimated from numerical evidence obtained in the corresponding evaluation study, and the variance of the distribution, reflecting both variability in the evaluation survey samples and other uncertainties in our knowledge about the component error, is estimated from internal evidence within the evaluation study and additional professional judgment when necessary. After assembling our best information about each of the component errors, we combine the information to produce a total survey error distribution, using a Monte Carlo method.

Before proceeding to consider the component errors, we introduce some notation that will be helpful in this section. Let μ_0 denote the true but unknown vaccination coverage in the age-eligible population of children and let $\hat{\mu}$ denote the NIS-Child estimate of the vaccination coverage. The TSE in vaccination coverage estimate is then given by

$$q_0 = \hat{\mu} - \mu_0 . \quad (1)$$

We use a three-stage model for TSE, where Stage 1 represents error due to the sampling frame's undercoverage of the population of age-eligible children, Stage 2 represents error due to nonresponse among sampled units, and Stage 3 represents measurement error among the responding units. The model for the first stage (sampling-frame coverage) is

$$\mu_0 = (1 - p_{1A})\mu_1 + p_{1A}\mu_{1A} , \quad (2)$$

where μ_1 is the true vaccination coverage for the age-eligible children covered by the sampling frame, μ_{1A} is the true vaccination coverage for the age-eligible children not covered by the sampling frame, and p_{1A} is the proportion of the age-eligible population not covered by the sampling frame. The model at the second stage (response) is

$$\mu_1 = (1 - p_{2A})\mu_2 + p_{2A}\mu_{2A} , \quad (3)$$

where μ_2 is the true vaccination coverage for children who respond to NIS-Child, μ_{2A} is the true vaccination coverage for children who do not respond, and p_{2A} is the proportion of children who do not respond. Finally, the model at the third stage (measurement) is

$$\mu_2 = (1 - p_{3A})\mu_3 + p_{3A}\mu_{3A} , \quad (4)$$

where μ_3 is the true vaccination coverage of children for whom accurate response is given to the survey, μ_{3A} is the true vaccination coverage of children for whom inaccurate response is given to the survey, and p_{3A} is the proportion of children for whom inaccurate response is given.

Combining all three stages together, the true vaccination coverage can be written as

$$\mu_0 = (1 - p_{1A})[(1 - p_{2A})\{(1 - p_{3A}) + p_{3A}\mu_{3A}\} + p_{2A}\mu_{2A}] + p_{1A}\mu_{1A} . \quad (5)$$

We can also write the TSE as

$$q_0 = q_1 + q_2 + q_3 , \quad (6)$$

where $q_1 = \mu_1 - \mu_0$ is the error due to noncoverage, $q_2 = \mu_2 - \mu_1$ is the error due to nonresponse, and $q_3 = \hat{\mu} - \mu_2$ is the error due to inaccurate reporting by survey respondents.

The seven parameters on the right side of (5) are $\phi = (\mu_{1A}, \mu_{2A}, \mu_{3A}, \mu_3, p_{1A}, p_{2A}, p_{3A})'$. Estimates of the values of these seven parameters, based on the analyses to be presented in Sections 3.2 through 3.4, are denoted by $\hat{\phi} = (\hat{\mu}_{1A}, \hat{\mu}_{2A}, \hat{\mu}_{3A}, \hat{\mu}_3, \hat{p}_{1A}, \hat{p}_{2A}, \hat{p}_{3A})'$. Let $\hat{\Sigma}$ denote the estimated variance-covariance matrix of ϕ . We assume the seven parameters are independently distributed and that $\hat{\Sigma} = \text{diag}(\hat{\sigma}_{\mu_{1A}}^2, \hat{\sigma}_{\mu_{2A}}^2, \hat{\sigma}_{\mu_{3A}}^2, \hat{\sigma}_{\mu_3}^2, \hat{\sigma}_{p_{1A}}^2, \hat{\sigma}_{p_{2A}}^2, \hat{\sigma}_{p_{3A}}^2)'$, where each $\hat{\sigma}^2$ is our estimate of the variance of the corresponding parameter.

We assume our knowledge about the true parameters ϕ , can be acceptably represented by a probability distribution, with parameters $\hat{\phi}$ and $\hat{\Sigma}$. We assess TSE by making random draws of ϕ from its distributions. For each draw, we use (5) to produce a draw from the distribution of true vaccination coverage in the overall age-eligible population (say, μ_0^*) and we compute $q^* = \hat{\mu} - \mu_0^*$ as a draw from the distribution of TSE. We obtain the distribution of TSE through 10,000 such draws.

Having established our model and notation, we now consider *sampling-frame coverage error* in the NIS-Child, which arises because the sampling frame omits direct representation of the phoneless and landline only (LLO) populations. Second, we consider *nonresponse error* in the NIS-Child, which comes about due to nonresponse in the random digit dial (RDD) telephone survey of households, failure of the parental respondent to give consent to contact the children's immunization providers, and missing

vaccination histories in the Provider Record Check given consent. Third, we consider *response or measurement error* in the provider reporting of vaccination histories. This component of error has also been referred to as under-ascertainment of vaccination histories. Fourth, we consider error in the NIS-Child due to sampling, i.e., error because the survey observes only approximately 1 out of 300 children in the age-eligible population. Fifth, we combine the foregoing component error distributions, resulting in the TSE distribution of the vaccination coverage estimate for the 2022 NIS-Child. Finally, we close this part of the report by examining the change in the TSE from the 2021 NIS-Child to the 2022 NIS-Child using the bridging cohort method, developed and implemented by Yankey et al. (2015).

3.1 Sampling-Frame Coverage Error

Sampling-frame coverage errors arise in a survey when the sampling frame does not include the entire target population. In 2018, the NIS-Child began using a single-frame cell-phone RDD design, which omits direct representation of children in LLO and phoneless households. To account for the excluded population groups, the NIS-Child weighting methodology makes adjustment to the weights by raking the weights to select demographic characteristics of the population of children 19 to 35 months. The assumption embedded in this procedure is that, after controlling for these characteristics, the vaccination coverage in the population not represented on the sampling frame equals the coverage in the population represented on the frame. However, it is possible that estimated vaccination coverage of children in the omitted domains experience different vaccination coverage than the domains of children included in the survey, namely, cell-phone-only (CPO) children and dual-user children, which may introduce bias into the estimator of vaccination coverage.

In this subsection, we attempt to measure the bias in estimated vaccination coverage introduced by sampling-frame coverage error. Table 3.1 displays the proportion of 19- to 35-month-old children in the population by telephone status for 2012 to 2021 based on estimates from the NHIS. The proportion of children with CPO status is increasing throughout this period and the proportion of children with dual-user status is decreasing. The estimated proportion in cell-phone households (i.e., CPO and dual-user combined), was relatively steady until 2018, before increasing from 93.3% in 2018 to 98.2% in 2019. This estimate remained at a similar level in 2020 (98.7%) and 2021 (97.8%). LLO children have decreased in prevalence over time. Estimates of the phoneless population increased between 2012 and 2018 before lower estimates were found in 2019, 2020, and 2021 (0.7%, 0.9%, and 1.2% respectively).

Table 3.1: Percentage of Age-Eligible Children in the Population by Telephone Status by Year: NIS-Child, United States, 2012-2021

Year	Cell-Phone Only	Dual-User	Landline Only	Phoneless
2012	51.3	43.4	4.0	1.3
2013	57.6	36.8	3.0	2.6
2014	64.1	30.8	2.6	2.5
2015	68.9	26.5	2.2	2.4
2016	71.8	24.6	1.3	2.4
2017	73.3	20.9	2.5	3.3
2018	74.0	19.3	1.6	5.1
2019	80.9	17.3	1.1	0.7
2020	82.5	16.2	0.4	0.9
2021	87.2	10.6	1.0	1.2

Source: Produced using the methods of Blumberg, Ganesh, Luke, and Gonzales (2013) applied to data from the 2012-2021 National Health Interview Survey sponsored by CDC's National Center for Health Statistics (<https://www.cdc.gov/nchs/nhis/index.htm>).

The 2022 NIS-Child did not directly measure LLO or phoneless children, and to assess vaccination coverage in these domains and determine whether they differ from estimates in the combined cell-phone domain, we must turn to other sources. Specifically, the 2012-2017 NIS-Child sampled and directly represented LLO children, thus permitting comparison of the vaccination coverage by telephone status. Table 3.2 displays the vaccination coverage estimates for 2017, the closest such year to 2022. We observe that vaccination coverage estimates are generally higher in the cell-phone domain than in the LLO domain, and four of the nine differences in estimates of vaccination coverage are statistically significant.

Since NIS-Child has never included direct sampling of phoneless children, we study vaccination coverage in the phoneless domain using estimates from the 2012 National Health Interview Survey-Provider Record Check (NHIS-PRC).¹⁶ Table 3.3 shows the vaccination coverage estimates for select vaccines and vaccine series for children in the cell-phone domain compared with those in the phoneless domain. For most of the vaccines presented, we observe higher vaccination coverage estimates from the cell-phone domain compared to the phoneless domain; however, none of the differences are statistically significant, likely due to the small number of phoneless children in the NHIS.

¹⁶ 2012 was the last, and therefore most recent, year for which the NHIS-PRC was conducted, and thus for which a direct measurement was obtained of the vaccination status of phoneless children.

Table 3.2: Vaccination Coverage Estimates and Standard Errors of Select Vaccines and Vaccine Series for the Cell-Phone and LLO Domains: NIS-Child, United States, 2017

Variance/Series	Cell-Phone Domain		Landline-Only Domain		Difference		
	Estimate	Standard Error	Estimate	Standard Error	Estimate	Standard Error	
4+DTaP	83.4	0.59	58.7	10.65	24.6	10.66	*
3+Polio	92.9	0.39	67.6	11.28	25.3	11.28	*
1+MMR	91.6	0.43	80.0	7.82	11.5	7.83	
Hib-FS	80.9	0.66	58.7	10.68	22.1	10.70	*
3+HepB	91.5	0.46	81.1	7.77	10.4	7.78	
HepB Birth Dose	73.7	0.80	70.1	8.07	3.6	8.12	
1+Var	91.2	0.44	72.6	8.64	18.6	8.66	*
4+PCV	82.6	0.64	62.0	10.83	20.6	10.85	
7-Vaccine Series	70.6	0.75	54.0	10.23	16.6	10.26	

* $p \leq 0.05$.

Note that 2012 NHIS-PRC estimates for HepB birth dose are not available. To assess coverage error in the HepB birth dose estimate, we used a conservatively high estimate of the difference between the vaccination coverage for the cell-phone and phoneless domains. We used this approach to demonstrate in subsequent analysis that coverage error is small even if the difference in vaccination coverage between the covered and non-covered domains is large. Specifically, for HepB birth dose, we used the largest estimated difference available for the eight other vaccine series.

The foregoing tables can be translated into an assessment of sampling-frame coverage error in the 2022 NIS-Child estimated vaccination coverage. We can also write the true vaccination coverage as

$$\mu_0 = \mu_1 - B, \quad (7)$$

where $B = p_{1A}(\mu_1 - \mu_{1A})$ equates to sampling-frame coverage error. To fully assess the distribution of total survey error in the NIS-Child, we will require estimates of the parameters, $\hat{p}_{1A}$, $\hat{\mu}_{1A}$, and $\hat{\mu}_1$, and their standard errors, which we present in Section 3.5. Here we simply observe that $\hat{p}_{1A}$ is obtained from the landline only and phoneless columns on the right side of Table 3.1 for the most recent year available 2021, and $\hat{\mu}_{1A}$ is obtained from the results of the 2022 NIS-Child and the Difference columns on the right side of Tables 3.2 and 3.3. The estimate of vaccination coverage in the sampling-frame covered population, $\hat{\mu}_1$, is obtained from the results of the 2022 NIS-Child and from analyses presented in Sections 3.2 and 3.3 on nonresponse error and measurement error.

Table 3.3: Vaccination Coverage Estimates and Standard Errors of Select Vaccines and Vaccine Series for Children 19-35 Months in the Cell-Phone and Phoneless Domains: NHIS-PRC, United States, 2012

Vaccine	Cell-Phone Domain		Phoneless Domain		Difference	
	Estimate	Standard Error	Estimate	Standard Error	Estimate	Standard Error
4+DTaP	83.87	1.36	87.40	6.53	-3.53	6.67
3+Polio	93.90	0.82	91.10	5.61	2.80	5.67
1+MMR	92.24	1.08	92.70	4.44	-0.46	4.57
Hib-PS	94.72	0.89	91.10	5.61	3.62	5.68
3+HepB	91.06	1.03	85.30	7.81	5.76	7.87
HepB Birth Dose					6.47 [#]	5.68 [#]
1+Var	91.69	0.98	92.70	4.44	-1.01	4.55
4+PCV	85.37	1.32	78.90	8.27	6.47	8.37
7-Vaccine Series	72.53	1.71	67.80	9.85	4.73	9.99

Notes: Estimates for the Hib full series (Hib-FS) are not available from the NHIS-PRC. Instead, we use the estimate for the Hib primary series (Hib-PS), which is ≥ 2 doses or ≥ 3 doses depending on brand. The estimates for the combined 7-vaccine series in this table are also based on Hib-PS rather than Hib-FS.

* $p \leq 0.05$.

[#] Estimates for HepB birth dose are not available from the NHIS-PRC Analysis Report. As inputs for estimating coverage error for the HepB birth dose, we used the largest difference in vaccination coverage estimates between the cell-phone and phoneless domains available from the eight other vaccines. This approach was chosen to be conservative and overestimate the extent of potential coverage error. For the standard error of the difference, we used the same standard error as for the corresponding estimate for 3+ Hib, as 3+ Hib and HepB birth dose have similar 2022 vaccination coverage estimates.

As a preliminary assessment of the effect of sampling-frame coverage error, we estimate the true vaccination coverage ignoring the effects of nonresponse and measurement error. In this circumstance, the NIS-Child vaccination coverage estimate is essentially μ_1 . Then, Table 3.4 presents estimates of B and of the true vaccination coverage, μ_0 . We find that sampling-frame coverage error is 0.3 percentage points or less and the estimated error is less than the standard error of μ_0 .

Table 3.4: Preliminary Assessment of Sampling-Frame Coverage Error and Mean True Vaccination Coverage (in %): NIS-Child, United States, 2022

Vaccine	$\hat{\mu}_1$ (2022 NIS-Child Vaccination Coverage Estimate)	$\hat{B}^a$	$\hat{\mu}_0$ (Mean of μ_0 , the True 2022 Vaccination Coverage)	Standard Error of μ_0
4+DTaP	84.5	0.2	84.3	0.6
3+Polio	93.5	0.3	93.2	0.4
1+MMR	93.0	0.1	92.9	0.4
Hib-FS	81.3	0.3	81.0	0.6
3+HepB	92.9	0.2	92.7	0.4
HepB Birth Dose	81.6	0.1	81.5	0.6
1+Var	92.6	0.2	92.4	0.4
4+PCV	83.8	0.3	83.6	0.6
7-Vaccine Series	72.1	0.2	71.9	0.7

^a The estimated sampling-frame coverage error, $\hat{B}$, is obtained by combining information in Table 3.2 about the landline-only population in 2017 with information in Table 3.3 about the phoneless population in 2012.

3.2 Nonresponse Error

There are two types of nonresponse error impacting NIS-Child, unit nonresponse error due to not obtaining responses (or completed interviews) for all children sampled and item nonresponse error due to missing questionnaire items among survey respondents. This section focuses on assessing survey error due to unit nonresponse. We conclude with a review of 2022 NIS-Child item nonresponse rates. NIS-Child vaccination coverage estimates are based on provider-reported vaccination histories; incomplete (or missing vaccination) information on these histories is a form of measurement error or under-reporting error, which is assessed in Section 3.3.

Components of Nonresponse in NIS-Child

Unit nonresponse error in NIS-Child estimates of vaccination coverage is the error arising because responses are not obtained for all children sampled. Nonresponse arises at four steps in the survey process, as follows: (1) failure to resolve the selected telephone number as an occupied household or some other known entity, (2) failure to screen the household for the presence of one or more age-eligible children, (3) failure to complete the interview of an eligible household, and (4) failure to obtain consent to contact the child's vaccination providers or failure to obtain sufficient information from providers to determine the child's vaccination status, given consent. We do not observe the vaccination

statuses of children for whom the household interview or the Provider Record Check is missing. This subsection assesses the extent of nonresponse error in the 2022 NIS-Child estimates of vaccination coverage for four vaccines or vaccine series, including 4+DTaP, 1+MMR, HepB birth dose, and the combined 7-vaccine series.

Weight Adjustment for Nonresponse Error

NIS-Child addresses error due to nonresponse by using weight adjustments that correct for known differences between children in responding and nonresponding households based on observable characteristics. Specifically, weighting cells are defined based on sample-frame information known for both respondents and nonrespondents, and weights are adjusted by a factor inversely proportional to the response rates within each cell. Calibration of the weights to demographic population totals also serves to adjust for differences between the responding sample and the population. The NIS-Child weighting methodology is described in detail in Wolter et al. (2017).

The weighting adjustment method assumes that nonresponse is a *missing at random* process (Rubin 1976), or that the conditional distribution of vaccination coverage on the characteristics used to form the weighting cells and calibration dimensions is the same whether or not the data are missing. This assumption, while widely used for weighting nonresponse adjustments, is generally untestable since we do not observe vaccinations statuses for the nonrespondents. Thus, further methods are needed to assess the extent of nonresponse error after conducting weighting adjustments.

Assessment of Nonresponse Error

To inform our TSE models, an estimate of the proportion of children with adequate provider data among children in households corresponding to the sampled telephone numbers is needed. The 2022 NIS-Child realization rate¹⁷ of children with adequate provider data was 2.7 percent with a standard error of 0.04 percentage points. Dividing the realization rate by the coverage rate of the sampling frames as estimated in Section 3.1 yields an estimate of the proportion of children with adequate provider data among those covered by the sampling frame of 2.8 percent, or 97.2 percent without adequate provider data, with a standard error of 0.5 percentage points. These two numbers (97.2% with a standard error of 0.5 percentage points) serve as model inputs $\hat{p}_{2A}$ and $\hat{\sigma}_{p2A}$ for the TSE analysis.

We now assess the extent of nonresponse error both before conducting nonresponse weighting adjustments as well as the residual error after accounting for such adjustments. It is common in TSE analyses to compare estimates derived from the survey under study, NIS-Child in this instance, with those from leading reference surveys (Biemer, 2010). A reasonable benchmark for the NIS-Child is the NHIS, because it provides representation of the same population of children as the NIS-Child and is

¹⁷ The realization rate (Skalland, 2011) is calculated as the ratio of the unadjusted survey estimate of the size of the target population to an external estimate of the true size of the target population and can be interpreted as the product of the coverage rate of the sampling frame and the response rate.

known to be a premier health survey of the general population in the United States. The NHIS is conducted using face-to-face interviewing methods, and has a relatively high response rate, with the final response rates for the Sample Child component in 2021 and 2022 being 49.9% and 45.8%.^{18,19} We combined two years of NHIS data to improve the accuracy of estimates and increase the sample size for young children.

Comparing NIS-Child estimates to those based on the NHIS enables estimation of nonresponse error. If nonresponse error is minimal in the NHIS, then the comparison to the NIS-Child can be taken as a measure of nonresponse error in the NIS-Child. To ensure comparability with the population covered by the NIS-Child, we examine NHIS children who are in the corresponding age range and have a working cell-phone in the family.

While the NHIS does not collect vaccination data for children and thus does not produce direct estimates of vaccination coverage, we can compare indirect vaccination coverage estimates derived from the NHIS to the direct estimates of vaccination coverage derived from the NIS-Child. We take advantage of the range of variables that are common to both the 2022 NIS-Child and the 2021 and 2022 NHIS and produce estimates of nonresponse error for four vaccination coverage estimates: 4+DTaP, 1+MMR, HepB birth dose, and the combined 7-vaccine series. Specifically, we estimate logistic regression models for vaccination statuses in the NIS-Child employing variables common to both surveys as independent variables and then use these models to produce multiple imputations of vaccination statuses for the NHIS case set, using the 2021 and 2022 NHIS Public Use Files (PUFs). Then, we estimate vaccination coverage using the NHIS data after pooling the survey-weighted estimates across the multiply-imputed datasets. We treat the estimates based on imputations of the NHIS as the true vaccination coverage among the population covered by the NIS-Child and estimate nonresponse error in the NIS-Child estimates by taking the difference between the NIS-Child and the pooled NHIS estimates.

We note that a common method for nonresponse bias analysis is to apply modeling, including logistic regression, to develop predictions or imputations of key variables among nonrespondents to develop full-response key estimates and compare to estimates based on respondents alone (U.S. Census Bureau, 2019). The method we employ in this study extends this concept to applying predictions or imputations to a reference survey. The 2009 report of the NCES/NISS Task Force on Nonresponse Bias Analysis recommends producing multiple imputations when employing such methods to account for imputation modeling variance in estimates of nonresponse bias.²⁰

Table 3.5 compares the estimates of vaccination coverage based on the NHIS imputed data and NIS-Child provider-reported data. Two NIS-Child estimates are presented, one based on applying design weights and another based on applying the final weights that reflect adjustments for noncoverage and nonresponse. Presenting both sets of estimates shows how the NIS-Child estimates, before and after

¹⁸ See p. 26 of https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2021/srvydesc-508.pdf

¹⁹ See p. 26 of https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2022/srvydesc-508.pdf

²⁰ Details of our methods for estimating nonresponse error are available from the authors.

weighting adjustments that account for nonresponse, compare to the estimates based on NHIS imputations. The table further shows the percentage point difference between the NHIS-based estimate and the NIS-Child estimate based on design weights. It includes a t -statistic for testing the difference between the two vaccination coverage estimates, accounting for the uncertainty in both estimates.

Table 3.5: Estimates of Nonresponse Error for Vaccination Coverage (%) Derived from Estimates Based on NHIS Imputations and NIS-Child Estimates

Statistics	4+ DTaP	1+ MMR	HepB Birth Dose	7-Vaccine Series
(a) Estimate Based on NHIS Imputations	84.1	92.4	81.8	73.5
Standard Error	1.6	1.3	1.7	2.1
(b) NIS-Child Estimate (Design Weighted)	84.3	92.2	80.2	73.7
Standard Error	0.8	0.6	0.8	0.8
(c) NIS-Child Estimate (Final Weighted)	84.5	93.0	81.6	72.1
Standard Error	0.6	0.4	0.6	0.7
(d) Difference, (b) – (a)	0.2	-0.1	-1.6	0.2
Standard Error of Difference	1.8	1.4	1.9	2.2
t -statistic	0.09	-0.09	-0.83	0.10
p -value (2-sided)	0.93	0.93	0.41	0.92
(d) Difference, (c) – (a)	0.4	0.6	-0.2	-1.4
Standard Error of Difference	1.7	1.3	1.8	2.2
t -statistic	0.23	0.45	-0.13	-0.62
p -value (2-sided)	0.81	0.65	0.90	0.54

The NIS-Child estimates based on design weights are 0.2 percentage points higher than the estimate based on NHIS imputations for 4+ DTaP, 0.1 percentage points lower for 1+ MMR, 1.6 percentage points lower for HepB birth dose, and 0.2 percentage point higher for the combined 7-vaccine series. None of these differences are statistically significant. For the TSE model, we base our estimates of $\hat{\mu}_{2A}$ and $\hat{\sigma}_{\mu 2A}$ on these differences by taking (b) – (a) as the difference in estimates between a full-response dataset and the respondent set and then using our estimate of $\hat{p}_{2A}$ above to derive $\hat{\mu}_{2A}$ as an estimate of the vaccination coverage among nonrespondents.

When applying final weights, the NIS-Child estimates are 0.4 percentage higher than the estimate based on NHIS imputations for 4+ DTaP, 0.6 percentage points higher for 1+ MMR, 0.2 percentage points lower for HepB birth dose, and 1.4 percentage points lower for the combined 7-vaccine series. Once again, none of these differences are statistically significant. Overall, when viewing the estimates based on NHIS imputations as the full-response estimate of vaccination coverage, these results indicate that nonresponse error in these four NIS-Child estimates is modest, although the standard errors reflect uncertainty in our knowledge about the extent of nonresponse error.

One caveat is that the results depend on the fit of the models used for imputation and the assumption that the conditional distributions of the NHIS case and NIS-Child case vaccination statuses on the

model variables are the same. The goodness-of-fit for the imputation models is not particularly strong ($\text{pseudo-}R^2 \leq 0.10$), resulting in fairly large standard errors for estimates based on NHIS imputations. This fact further illuminates the extent of uncertainty in our estimates of nonresponse error.

NIS-Child Item Nonresponse Rates

Thus far, this section has focused on assessing error in vaccination coverage rates due to unit nonresponse to NIS-Child. Here, we present item nonresponse rates for the household interview portion of the survey in Table 3.6, focusing on socio-demographic variables used in raking procedures for survey weighting. The item nonresponse rates in this table for variables used in raking, all variables except income, are low and less than five percent. This indicates low risk for impact on vaccination coverage estimates. We also include exact family income which has a higher item nonresponse rate of 22.9%, although the majority of exact-income nonrespondents completed the follow-up cascade of income questions, which establish tight income bounds.

Table 3.6: Item Nonresponse Rates, NIS-Child Household Interview, United States, 2022

Variable	2022 Item Nonresponse Rate (Percent)*
Sex of child	0.5
Hispanic ethnicity of child	0.7
Race of child	4.6
Education of mother	0.9
Household phone status – landline-only, cell-phone-only, or landline- and cell-phone	0.4
Family income	22.9
Exact income not reported but income cascade completed	15.7
Exact income not reported and income cascade not completed	7.2

* Unweighted percent of "don't know" or "refused" responses among respondents asked the question. For race of child, percent also includes "other" responses that could not be back-coded into one or more of the race categories presented in the questionnaire. Rates presented in this table exclude U.S. territories.

3.3 Measurement Error

In this subsection, we assess provider under-reporting of the child's vaccination status. Throughout, we assume that if a provider reported a vaccination, it was given. We consider a child to have under-reported vaccination status if the child is truly up-to-date for the vaccine but the child is classified as not up-to-date based on the vaccination history reported by the child's provider(s). That is, children with under-reporting are up-to-date but are reported as not up-to-date; children without under-reporting are either both truly up-to-date and reported as up-to-date, or are truly not up-to-date and are reported as not up-to-date. Note that all children with under-reporting are, by definition, truly up-to-date.

To assess under-reporting in provider-reported vaccination histories, we rely on projects sponsored by CDC in which the 2017 and 2019 NIS-Child samples of children in selected states were matched to the state or local IIS. For each of these projects, the NIS-Child interview requested parental consent to contact both the child's vaccination providers and the local IIS. Children for whom consent was obtained were matched to their respective IIS databases. Then, for the set of matched children, we compared each child's vaccination status based on the provider report(s) to the child's vaccination status when both the provider(s) and the IIS reports are included in a combined vaccination history.

We take the combined history to offer the best available information about the child's true vaccination status, and we view the NIS-Child provider-reported history to be possibly subject to an under-reporting mechanism. This mechanism, often called under-ascertainment, can arise if some but not all of the child's providers were nominated by the household respondent, if the nominated provider's contact information was reported incorrectly by the household respondent, if not all nominated providers responded to the mailed Provider Record Check, or if respondent providers did not have complete vaccination records (such as when a child moved out-of-area and vaccination records were not forwarded).

From these studies, we estimated the proportion of children with under-reported vaccination status. For each given vaccine, we determined the subset of matched children for whom measured vaccination status (i.e., up-to-date or not up-to-date) from the combined (provider and IIS) vaccination history was equivalent to the vaccination status from the NIS-Child provider-reported vaccination history alone. Then we made the reasonable assumption that equivalence of the measured vaccination statuses is a sign of accurate reporting in the NIS-Child Provider Record Check. In other words, if the IIS did not add information about vaccination status beyond that already embodied within the NIS-Child provider-reported data, then we took the NIS-Child data to be accurate (not under-reported). If the child was up-to-date based on the combined (provider and IIS) vaccination history but not up-to-date based on the NIS-Child vaccination history alone, then we classified the child as having their vaccination status under-reported in the NIS-Child. Of the children with adequate NIS-Child provider data that were located in the IIS and had two or more doses in the IIS, we estimated the NIS-Child under-reporting rate for the vaccine as the design-weighted proportion classified as having under-reported vaccination status for the vaccine.

Recent sources of information for assessing under-reporting in the NIS-Child are the match projects completed in 2017 and 2019. In 2017, match projects were conducted in 21 jurisdictions: Arkansas, Connecticut, Georgia, Idaho, Iowa, Louisiana, Maine, Michigan, Mississippi, Nevada, New Mexico, New York City, North Carolina, North Dakota, Oklahoma, Rhode Island, South Dakota, Vermont, Washington, Wisconsin, and Wyoming. In 2019, match projects were conducted in 7 jurisdictions: Arkansas, Kansas, Louisiana, Missouri, Nevada, New York City, and Vermont. Because only a subset of jurisdictions participated in match projects, we estimated the standard error of the under-reporting rate by treating each selected jurisdiction as a cluster sampled from the population of jurisdictions.

Table 3.7 presents the estimated under-reporting error for the vaccines and vaccine series under study.

Table 3.7: Estimated Under-Reporting Error by Vaccine Series: NIS-Child, United States, 2017 and 2019

Vaccine	Under-Reporting Error	
	Estimate (percentage points)	Standard Error (percentage points)
Combined 7-vaccine series	8.3	0.57
≥4 DTaP	4.7	0.38
≥3 Polio	2.1	0.25
≥1 MMR	2.7	0.28
Hib-FS	5.0	0.46
≥3 HepB*	2.8	0.31
HepB birth dose	3.3	0.31
≥1 VRC at or after age 12 months	2.5	0.27
≥4 PCV	3.7	0.35

Note: National-level under-reporting in NIS-Child provider-reported vaccination status was estimated using data from the 2017 and 2019 IIS-NIS Match Projects. Among children with adequate provider data found in the IIS database with two or more IIS doses, those classified as up-to-date based on the combined IIS-NIS vaccination history but not up-to-date based on the NIS-Child vaccination history alone were considered to have under-reported NIS-Child vaccination status.

*Estimates for ≥3 HepB do not incorporate data from North Dakota, as data were not available.

3.4 Sampling Error

Sampling error is the error arising since we do not observe the entire population, only a random sample of the population. Table 3.8 presents estimated vaccination coverage and their standard errors for 2022 NIS-Child, using the Taylor series method. The standard errors are calculated first for the design-weighted vaccination coverage estimate and then for the final-weighted vaccination coverage estimate. The design weights reflect the sample design but do not include adjustments for noncoverage, nonresponse, or calibration to population control totals. Final weights are the design weights adjusted for noncoverage, nonresponse, and calibration to population control totals.

The national-level standard errors are estimated to be small, ranging from approximately 0.4 to about 0.7 percentage points for final-weighted estimates.

Table 3.8: Vaccination Coverage Estimates and Standard Errors Using Design Weights and Final Weights: NIS-Child, United States, 2022

Vaccine	Design Weighted		Final Weighted	
	Estimate (%)	Standard Error (percentage points)	Estimate (%)	Standard Error (percentage points)
7-Vaccine Series	73.7	0.84	72.1	0.70
4+ DTaP	84.3	0.84	84.5	0.59
3+ Polio	92.0	0.77	93.5	0.41
1+ MMR	92.2	0.58	93.0	0.38
Hib-FS	81.6	0.79	81.3	0.61
3+ HepB	91.5	0.72	92.9	0.39
HepB birth dose	80.2	0.82	81.6	0.58
1+ VRC at or after age 12 months	91.8	0.58	92.6	0.39
4+ PCV	84.7	0.79	83.8	0.60

Note: Excludes U.S. territory samples.

3.5 Total Survey Error Distribution

This subsection consolidates the component assessments of sampling-frame coverage error (Section 3.1), nonresponse error (Section 3.2), measurement error (Section 3.3), and sampling error (Section 3.4), resulting in an assessment of the total survey error in the 2022 NIS-Child estimated vaccination coverage. We focus the overall assessment on four estimates of vaccination coverage corresponding to 4+DTaP, 1+MMR, HepB birth dose, and the combined 7-vaccine series. The subsection culminates with the presentation of total survey error distributions, constructed using the methodology described in Molinari, Wolter, Skalland, et al. (2011) and Wolter, Pineau, Skalland, et al. (2017). For each estimate, we review the distribution of total survey error across 10,000 Monte Carlo simulations, treating the mean of the distribution as the point estimate of total error and the interval between the 2.5th percentile and the 97.5th percentile as the 95% credible interval of total error.

At the beginning of Part II of this report, we presented our TSE model and its seven parameters. Table 3.9 contains the values of these seven parameters and their standard errors we used in the model for TSE in the 2022 NIS-Child. These values arise from the analyses described in Sections 3.2 through 3.4 above.²¹ We assume the logit transformations of the inputs are normally distributed and independent (i.e., no covariance between inputs).

²¹ $\hat{\mu}_{1A}$ and $\hat{\mu}_{2A}$, which were estimated based on the NHIS-PRC and models built from NIS-Child vaccination data, respectively, have been adjusted upwards to account for provider under-reporting error in those surveys, assuming the same level of under-reporting error as was estimated in Section 3.4.

Table 3.9: Total Survey Error Model Inputs by Stages: NIS-Child, United States, 2022

Parameter	4+ DTaP	1+ MMR	HepB Birth Dose	7-Vaccine Series
Stage 1: Sampling-Frame Coverage Error (LLO and Phoneless Households)				
$\hat{p}_{1A}$	2.2%	2.2%	2.2%	2.2%
$\hat{\sigma}_{p1A}$	0.5%	0.5%	0.5%	0.5%
$\hat{\mu}_{1A}$	80.0%	90.7%	79.7%	70.3%
$\hat{\sigma}_{\mu1A}$	7.3%	4.9%	5.2%	7.6%
Stage 2: Nonresponse Error				
$\hat{p}_{2A}$	97.2%	97.2%	97.2%	97.2%
$\hat{\sigma}_{p2A}$	0.5%	0.5%	0.5%	0.5%
$\hat{\mu}_{2A}$	88.8%	94.9%	85.2%	81.8%
$\hat{\sigma}_{\mu2A}$	1.7%	1.3%	1.8%	2.2%
Stage 3: Measurement Error				
$\hat{p}_{3A}$	4.7%	2.7%	3.4%	8.3%
$\hat{\sigma}_{p3A}$	0.4%	0.3%	0.3%	0.6%
$\hat{\mu}_{3A}$	100.0%	100.0%	100.0%	100.0%
$\hat{\sigma}_{\mu3A}$	0.0%	0.0%	0.0%	0.0%
$\hat{\mu}_3$	88.5%	94.8%	83.0%	80.4%
$\hat{\sigma}_{\mu3}$	0.9%	0.7%	0.9%	1.0%

Table 3.10 presents the total survey error distribution and component error distributions based on 10,000 Monte Carlo draws from the input parameter distributions and application of the TSE model. The means of the estimated TSE distributions are -4.0, -1.7, -3.3, and -9.2 percentage points for 4+ DTaP, 1+ MMR, HepB birth dose, and the combined 7-vaccine series, respectively, suggesting that the 2022 NIS-Child may have underestimated the true vaccination coverage. The largest estimated component of error in absolute value for all four vaccine series is measurement error, i.e., provider under-reporting error.

Table 3.10: Mean and 95% Credible Interval for the Estimated TSE Distribution and Component Error Distributions: National Immunization Survey-Child, United States, 2022

Vaccine or Series	Component	Mean TSE (percentage points)	95% Credible Interval (percentage points)
4+ DTaP	TSE (final weighted)	-4.0	(-6.9, -0.6)*
	TSE (design weighted)	-4.2	(-7.1, -0.8)*
	Noncoverage error	0.2	(-0.1, 0.7)
	Nonresponse error	0.2	(-3.2, 4.1)
	Measurement error	-4.7	(-6.3, -2.8)*
	Sampling error	0.0	(-1.7, 2.0)

Vaccine or Series	Component	Mean TSE (percentage points)	95% Credible Interval (percentage points)
1+ MMR	TSE (final weighted)	-1.7	(-3.8, 1.3)
	TSE (design weighted)	-2.4	(-4.5, 0.6)
	Noncoverage error	0.1	(-0.1, 0.4)
	Nonresponse error	0.1	(-2.4, 3.3)
	Measurement error	-2.6	(-3.8, -1.3)*
	Sampling error	0.1	(-1.2, 1.5)
HepB Birth Dose	TSE (final weighted)	-3.3	(-6.4, 0.3)
	TSE (design weighted)	-4.6	(-7.8, -1.1)*
	Noncoverage error	0.1	(-0.1, 0.4)
	Nonresponse error	-1.5	(-5.1, 2.5)
	Measurement error	-3.3	(-4.9, -1.6)*
	Sampling error	0.0	(-1.7, 1.8)
Combined 7-vaccine series	TSE (final weighted)	-9.2	(-13.1, -4.8)*
	TSE (design weighted)	-7.7	(-11.5, -3.2)*
	Noncoverage error	0.3	(0.0, 0.7)
	Nonresponse error	0.3	(-4.1, 5.1)
	Measurement error	-8.3	(-10.1, -6.3)*
	Sampling error	0.0	(-2.0, 2.2)

* 95% credible interval does not include 0.

3.6 Assessment of the Change in Bias Using the Bridging Cohort Method

The previous section assessed TSE in the 2022 NIS-Child estimated vaccination coverage, while the current section assesses the change in TSE between 2021 and 2022. Change is measured using the bridging cohort method introduced by Yankey et al. (2015). Each survey quarter includes children born in 20 monthly birth cohorts. Every pair of adjacent survey quarters spans 23 monthly birth cohorts, of which 17 are in common and 6 are not in common. In turn, every survey year represents 29 monthly birth cohorts. Every pair of adjacent survey years spans 39 monthly birth cohorts, of which 17 are in common and 22 are not in common. We shall call the 17 common months the *bridging cohort*, and for 2021 and 2022, the bridging cohort extends from children born in January 2019 through children born in May 2020.

Consider a vaccination coverage estimate for the bridging cohort as of a given child age, such as 19 months or 24 months. Two estimates are possible, one using the sample of children in the bridging cohort within the 2021 NIS-Child sample and the second using the corresponding sample of children within the 2022 NIS-Child sample. Ideally, the two estimators should exhibit the same expected value. A large difference between the two estimates may signal a change in the expectation from one survey year to the next, which could result from a change in the distribution of sampling-frame coverage error, nonresponse error, or measurement error. Differences may also result simply from the effects of random sampling error.

Table 3.11 presents the two estimates of vaccination coverage for children as of 19 months of age for the 2021-2022 bridging cohort. Estimates and standard errors are presented for several vaccines and vaccine series and for the proportion of unvaccinated children in the population. The columns on the right side of the table reveal the differences between the 2022 and 2021 estimates for the bridging cohort, the estimated standard errors of the differences, and the *p*-values associated with statistical tests of the hypothesis that the expectations of the two estimators are the same. For example, for the 4+ DTaP vaccination coverage estimate by 19 months, the difference is -0.2 percentage points with a standard error of 1.3; given the *p*-value of 0.87, the hypothesis of no change in expectation is not rejected. Summarizing, we do not observe any statistically significant differences between the 2022 and 2021 vaccination coverage estimates for the 2021-2022 bridging cohort. Overall, the results do not provide evidence of a change in the expectation of total survey error between 2021 and 2022.

Table 3.11: Difference between the Estimates* for the Bridging Birth Cohort† by Age 19 Months: NIS-Child, United States, 2021 vs. 2022

Description	2021		2022		Difference		
	Est	Std Error	Est	Std Error	Est	Std Error	p-value for Test of No Difference
3+ DTaP/DTP/DT by 19 months	93.5	0.46	93.1	0.59	-0.4	0.75	0.596
4+ DTaP/DTP/DT by 19 months	72.5	0.94	72.3	0.95	-0.2	1.34	0.873
3+ Polio by 19 months	92.5	0.49	91.7	0.63	-0.8	0.80	0.321
1+ MMR by 19 months	88.7	0.66	89.8	0.62	1.1	0.91	0.220
3+ Hib by 19 months	90.7	0.56	90.1	0.64	-0.7	0.86	0.445
Hib-PS by 19 months	93.1	0.49	93.0	0.57	-0.1	0.75	0.903
Hib-FS by 19 months	74.2	0.91	74.4	0.92	0.2	1.30	0.885
1+ Varicella by 19 months, excluding shots before 12 months	88.0	0.67	88.4	0.68	0.3	0.96	0.718
3+ Hepatitis B by 19 months	92.1	0.48	91.4	0.62	-0.7	0.78	0.377
3+ Pneumococcal by 19 months	92.3	0.54	92.2	0.63	-0.1	0.83	0.873
4+ Pneumococcal by 19 months	80.0	0.85	80.1	0.86	0.2	1.21	0.883
1+ Hepatitis A by 19 months	84.3	0.74	83.9	0.79	-0.4	1.08	0.729
2+ Hepatitis A by 19 months	29.9	0.96	28.1	0.88	-1.9	1.30	0.148
2+ or 3+ Rotavirus depending on type by 19 months	78.8	0.85	77.6	0.89	-1.2	1.23	0.331
7-series by 19 months	62.2	1.02	62.0	1.02	-0.1	1.44	0.920
1+ Hepatitis B-containing on day of birth or on day 1, 2 or 3 following birth	82.5	0.78	82.9	0.71	0.5	1.05	0.660
Unvaccinated children	0.78	0.13	0.75	0.11	0.0	0.17	0.871
2+ Flu by 19 months, doses at least 24 days apart	61.6	1.01	60.9	1.01	-0.7	1.42	0.611

* National-level estimates computed among children with adequate provider data, excluding children from U.S. territories.

† The bridging birth cohort used for this analysis of the 2021 and 2022 NIS-Child includes children born between January 2019 and May 2020.

4. Summary

We profiled the sources of error in 2022 NIS-Child statistics at the national level (excluding U.S. territories) for children aged 19 to 35 months. We compared NIS-Child statistics to corresponding values from benchmark surveys and other external sources (Part I) and assessed component and total error in vaccination coverage estimates through a series of specialized evaluation studies (Part II). Wherever possible, we used 2022 sources and studies to assess error in the 2022 NIS-Child. Where 2022 sources were not available, we reported information from prior year sources as the best information available for understanding error in the 2022 NIS-Child.

In Part I, we compared NIS-Child demographic distributions (child's age, child's sex, mother's race and ethnicity, mother's education, mother's age) to benchmark values derived from natality data supplied by the National Vital Statistics System. When using design weights that have not been calibrated to external population totals, demographic distributions as estimated in the survey are generally close to the population distributions. Before calibration of the weights to external population totals, the NIS-Child somewhat over-represented children whose mothers are college graduates, non-Hispanic White, or age 30 or greater. The survey somewhat under-represented children whose mothers are not college graduates, are Hispanic or non-Hispanic Black, or age 20 to 29. When using the final weights that have been calibrated to external population totals, the differences between survey and population narrowed, but the 2022 NIS-Child still over-represented children whose mothers are college graduates or are age 30 or older.

We compared NIS-Child vaccination coverage estimates to IISAR vaccination coverage estimates and generally found that NIS-Child estimates are higher. For the six 2013-2017 sentinel sites, we found good agreement between NIS-Child and IISAR estimates. Further, we determined that the child participation rate is a reasonable indicator of the quality of the corresponding IIS database. We learned that the difference between NIS-Child and IISAR vaccination coverage declines as the child participation rate increases (i.e., as the quality of the IIS increases). The findings are consistent with the hypothesis that IIS vaccination coverage estimates converge towards NIS-Child vaccination coverage estimates as the quality of the IIS increases.

We compared NIS-Child health insurance distributions to similar distributions produced by the ACS, CPS, and NHIS. The three surveys use somewhat different definitions of insurance status and different age ranges of children. Nevertheless, we found the three distributions to be broadly similar, but with some differences. The NIS-Child estimate of percent of children with any public insurance was higher than the corresponding estimates from ACS, CPS, and NHIS, and the NIS-Child estimate of the percent of children uninsured was lower than the estimates from the benchmark surveys.

We compared NIS-Child vaccination coverage estimates at the state level to corresponding estimates obtained from eight state immunization surveys. Some aspects of NIS-Child and state survey practices are hard to compare and limit the importance of the results. That said, we believe it is safe to conclude that there is reasonable agreement between NIS-Child and state vaccination coverage estimates in many of the states. Where NIS-Child and state results were comparable, we found similar vaccination coverage estimates. For state surveys that rely on IIS vaccination histories, we found NIS-Child estimates were generally higher than the corresponding states' estimates. While this work did not provide specific measures of error in NIS-Child statistics, we believe it did provide general support for the accuracy of the vaccination coverage estimates.

In Part II of the report, we assessed NIS-Child with respect to sampling-frame coverage error, nonresponse error, measurement error, sampling error, and total survey error. We also assessed the change in total survey error from 2021 to 2022.

As the NIS-Child cell-phone RDD sampling frame fails to include the landline only and phoneless populations, we assessed vaccination coverage estimates in the former using data collected in the 2017 NIS-Child and in the latter using data collected in the 2012 NHIS Provider Record Check. The vaccination coverage estimates in the population covered by the sampling frame were found to be higher than the vaccination coverage estimates in the uncovered population. Because the sampling-frame uncovered population is so small relative to the covered population, however, we found mean sampling-frame coverage error to be minimal, namely 0.3 percentage points or less, for all nine vaccines series studied.

We used the 2021 and 2022 NHIS in assessing nonresponse error in the 2022 NIS-Child. The NHIS does not offer direct estimates of vaccination coverage. Instead, we used a model-based technique to multiply impute NHIS vaccination status, and then compared the resulting NHIS vaccination coverage estimates (treated as estimates void of nonresponse error) to NIS-Child vaccination coverage estimates, with the difference treated as nonresponse error in the NIS-Child. Incorporating all sources of missing data, including (1) nonresolution of telephone numbers, (2) nonresponse to the screener, (3) failure to complete the interview, (4) non-consent to contact providers, and (5) nonresponse from providers, we estimated that over 90% of the sample failed to respond to the NIS-Child. Despite this large percentage, we found mean nonresponse error in vaccination coverage estimates to be modest and not statistically significant for all of the vaccine series examined.

We used 28 IIS-NIS match studies from 2017 and 2019 to assess measurement error, or under-ascertainment, in NIS-Child vaccination coverage estimates. In this work, the standard of truth for a given child is taken to be the synthesis of the NIS-Child and IIS vaccination histories. We found measurement error depressed observed vaccination coverage estimates by about two to eight percentage points. Under-ascertainment of a child's vaccination history may arise due to the failure of the household respondent to nominate all of the child's vaccination providers, failure of the nominated vaccination providers to respond, or failure of the responding providers to report all of the vaccinations that the child has received.

We combined the component errors and assessed the distribution of total error in the NIS-Child vaccination coverage estimates using a Monte Carlo technique. For the 4+DTaP vaccination coverage estimate, we found the mean of the total survey error distribution to be -4.0 percentage points with a 95% credible interval of (-6.9, -0.6) percentage points. That is, the NIS-Child vaccination coverage estimate was on average about 4.0 percentage points too low. For the 1+MMR vaccination coverage estimate, we found the mean of the TSE distribution to be -1.7 percentage points with a 95% credible interval of (-3.8, -1.3) percentage points. For the estimate of HepB birth dose vaccination coverage, the mean of the TSE distribution was -3.3 percentage points while the 95% credible interval of (-6.4, 0.3) percentage points includes 0. Finally, for the combined 7-vaccine series, we found the mean of the TSE distribution to be -9.2 percentage points with a 95% credible interval of (-13.1, -4.8) percentage points. Again, under-ascertainment of the provider-reported vaccination history dominated total survey error. Estimates of nonresponse error have wider 95% credible intervals because those estimates have greater uncertainty than estimates of other error components.

Finally, we conducted a bridging cohort analysis to assess the possibility of a change in expected value between the 2021 and 2022 NIS-Child by comparing vaccination coverage estimates between the two survey years for children born during a 19-month period included for both survey years. Among eighteen vaccine series examined, we found no statistically significant differences and no evidence of a change in mean TSE between 2021 and 2022.

Our results for the 2022 NIS-Child are subject to various limitations. The comparisons to benchmark distributions in Part I are flawed because the benchmark source usually uses somewhat different concepts or definitions than the NIS-Child. Our comparison of NIS-Child and IISAR vaccination coverage estimates is limited to the 7-vaccine series, and the findings may not apply to other vaccine series. In Part II, the results are based on input distributions for the component errors as estimated using our best available information from external sources and studies, but these inputs may not be accurate. While large-sample theory motivates our choice of the normal family of distributions, we have not validated this choice. Two key external sources of the information on component errors are the NHIS and state IIS. The NHIS is based on a smaller sample size than the NIS-Child, its NHIS Provider Record Check (used in the study of sampling-frame coverage error) is likely subject to many of the same measurement issues as the NIS-Child Provider Record Check, and it is subject to its own nonresponse and sampling-frame coverage errors. To study nonresponse error in the NIS-Child, we utilized imputed vaccination statuses in the NHIS rather than provider-reported statuses, because the NHIS Provider Record Check was terminated in 2013. IIS may underestimate vaccination coverage to some extent (e.g., to miss some resident children and some vaccine doses within included children), and completeness may vary substantially from one state or local area to the next. Our results are based on work with IIS in a subset of states that have conducted IIS-NIS match projects. Our results are also based on an assumption of independence of the component errors and this assumption might not be accurate. We conducted the TSE analysis for selected national-level vaccination coverage estimates, and the results do not necessarily extend to other vaccines, states or estimation areas, or socio-demographic domains.

References

Biemer, P. P. (2010). Total survey error: Design, implementation, and evaluation. *Public Opinion Quarterly*, 74(5), 817-848.

Lackmore, C. (2022). Results of the Survey of Immunization Levels in 2-Year-Old Children (2020). <http://www.floridahealth.gov/programs-and-services/immunization/resources/surveys/documents/2yo2020.pdf>

Blumberg, S.J., Ganesh, N., Luke J.V., and Gonzales G. (2013). Wireless substitution: State-level estimates from the National Health Interview Survey, 2012. National health statistics reports; no 70. Hyattsville, MD: National Center for Health Statistics. Available from: <https://www.cdc.gov/nchs/data/nhsr/nhsr070.pdf>

CDC (2022). National Health Interview Survey: 2021 Survey Description. Division of Health Interview Statistics, National Center for Health Statistics, U.S. Department of Health and Human Services. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2021/srvydesc-508.pdf

CDC (2023a). National Health Interview Survey: 2022 Survey Description. Division of Health Interview Statistics, National Center for Health Statistics, U.S. Department of Health and Human Services. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2022/srvydesc-508.pdf

CDC (2023b). National Immunization Survey-Teen: Error profile for the 2022 NIS-Teen. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA. <https://www.cdc.gov/vaccines/imz-managers/coverage/teenvaxview/downloads/error-profile-2022-nis-teen.pdf>

Georgia Department of Public Health (n.d.). GA immunization report for children 19-35 Months, 2022. https://immunizationstudyreports.s3.amazonaws.com/Child+Report/Child_Report_2022.html#summary

Geslois, J. (2022). Retrospective Vaccination Coverage Survey 2014-2015 results (School year 2018-2019). Kansas Department of Health and Environment, Topeka, KS. https://www.kdheks.gov/immunize/download/Retrospective_2017-2018.pdf

Michigan Department of Health & Human Services (n.d.). County immunization report cards. <https://www.michigan.gov/mdhhs/adult-child-serv/childrenfamilies/immunization/localhealthdepartment/county-immunization-report-card>

Molinari, N.M., Wolter, K., Skalland, B., Montgomery, R., Khare, M., Smith, P.J., Barron, M.L., Copeland, K., Santos, K., and Singleton, J.A. (2011). Quantifying bias in a health survey: Modeling total survey error in the National Immunization Survey. *Statistics in Medicine*, 30, 505-514.

National Institute of Statistical Sciences. (2009). NCES/NISS task force on nonresponse bias analysis: Final report.

Rubin, D. B. (1976). Inference and missing data. *Biometrika*, 63(3), 581-592.

Skalland, B. (2011). An alternative to the response rate for measuring a survey's realization of the target population. *Public Opinion Quarterly*, 75(1), 89-98.

Tennessee Department of Health (2022). Results of the 2022 Immunization Status Survey of 24-month-old children in Tennessee. <https://www.tn.gov/content/dam/tn/health/documents/cedep-weeklyreports/2022-24-Month-Old-Survey.pdf>

U.S. Census Bureau. (2019). 2017 National Survey of Children's Health: Nonresponse Bias Analysis.

Virginia Department of Health. (n.d.). Virginia Immunization Survey, SY 2021 Single antigen coverage rates (%) at 24 Months of age for PubKG, PrivKG, combined KG & DC. <https://www.vdh.virginia.gov/content/uploads/sites/11/2016/04/VAISAgRates.pdf>

Washington State Department of Health (n.d.). Immunization measures by county dashboard. <https://doh.wa.gov/data-and-statistical-reports/washington-tracking-network-wtn/immunization-data/county-public-health-measures-dashboard>

Wisconsin Department of Health Services (n.d.). Vaccination coverage among Wisconsin children by age 24 months, by vaccine or series, region of residence and year. <https://www.dhs.wisconsin.gov/publications/p02003a.pdf>

Wolter, K.M., Pineau, V.J., Skalland, B., Zeng, W., Singleton, J.A., Khare, M., Zhao, Z., Yankey, D., and Smith, P.J. (2017). Total survey error assessment for sociodemographic subgroups in the 2012 U.S. National Immunization Survey. In *Total Survey Error in Practice*, edited by Biemer, P.P., de Leeuw, E., Eckman, S., Edwards, B., Kreuter, F., Lyberg, L.E., Tucker, N.C., and West, B.T. John Wiley & Sons, Hoboken, New Jersey.

Wolter, K. M., Smith, P.J., Khare, M, Welch, B., Copeland, K. R., Pineau, V. J., and Davis, N. (2017). Statistical methodology of the National Immunization Survey, 2005-2014. *Vital and Health Statistics* 1(61). National Center for Health Statistics, Hyattsville, MD.

Yankey, D., Hill, H.A., Elam-Evans, L.D., Khare, M., Singleton, J.A., Pineau, V., and Wolter, K. (2015). Estimating change in telephone survey bias in an era of declining response rates and transition to wireless telephones – evidence from the National Immunization Survey (NIS), 1995-2013. Presented at the annual conference of the American Association for Public Opinion Research, Hollywood, FL.